Eli Lilly’s New Lineup: India Gets the Full Arsenal of Mounjaro KwikPens

Eli Lilly obtained Indian regulatory approval for its KwikPen formulation of Mounjaro (tirzepatide), a once-weekly injectable treatment used to treat type 2 diabetes and obesity. The pen is now available in all approved dose strengths—2.5 mg through 15 mg, giving patients a more convenient and easier-to-use alternative than vials.

 

Indian Medicines Controller's approval by the CDSCO is a positive move towards expanding access to advanced metabolic treatment. The KwikPen is a pre-filled, ready-to-use injection device designed to simplify injection and provide better compliance, especially for patients with chronic illness.

 

Mounjaro, which targets both GIP and GLP-1 receptors, has shown superior outcomes in sugar control and weight loss compared to the existing treatments for GLP-1. The drug, which hit Indian markets in March 2025, has seen rapid uptake since its launch, with revenue crossing ₹24 crore in three months.

 

Pen availability with the full gamut of dosages will fuel adoption even more, particularly since India has a twin epidemic of obesity and diabetes among over 100 million adults.

 

Sources: News18, Times of India, Business Standard